Review



pcdna myc deltan tcf4 expression vector  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Addgene inc pcdna myc deltan tcf4 expression vector
    Figure 2. <t>TCF4/TCF7L2</t> mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.
    Pcdna Myc Deltan Tcf4 Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcdna+myc+deltan+tcf4+expression+vector/pcDNA%2FMyc+DeltaN+TCF4+(Plasmid+%2316513)/10__1158_slash_2159___8290__cd___21___0680-318-1-6
    Average 93 stars, based on 17 article reviews
    pcdna myc deltan tcf4 expression vector - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer"

    Article Title: Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer

    Journal: Cancer Discovery

    doi: 10.1158/2159-8290.cd-21-0680

    Figure 2. TCF4/TCF7L2 mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.
    Figure Legend Snippet: Figure 2. TCF4/TCF7L2 mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.

    Techniques Used: Western Blot, Quantitative RT-PCR, Expressing, Sequencing, Binding Assay, ChIP-sequencing, Negative Control, Luciferase, Activity Assay, Dominant Negative Mutation

    Related Articles

    Expressing:

    Article Title: Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in <i>APC</i>-Mutated Colorectal Cancer
    Article Snippet: HEK 293T cells were seeded in 24-well plates and transfected with luciferase reporter vectors of pGL3-Basic (Promega; cat. #E1751), pGL3-hTDO2 promoter, or pGL3-hTDO2 promoter with a mutated TCF4 binding site with pRL Renilla Luciferase Control Reporter Vector (Promega; cat. #E2261) and pLV-beta-catenin ΔN90 (RRID:Addgene_36985) using Lipofectamine 2,000 reagent (Thermo Fisher Scientific; cat. #11668019). .. The pcDNA/Myc DeltaN TCF4 expression vector (RRID:Addgene_16513) was transfected to express dominant-negative TCF4. .. Luciferase activity was measured with DualLuciferase reagent (Promega; product code E1910) according to the manufacturer’s instructions.

    Plasmid Preparation:

    Article Title: Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in <i>APC</i>-Mutated Colorectal Cancer
    Article Snippet: HEK 293T cells were seeded in 24-well plates and transfected with luciferase reporter vectors of pGL3-Basic (Promega; cat. #E1751), pGL3-hTDO2 promoter, or pGL3-hTDO2 promoter with a mutated TCF4 binding site with pRL Renilla Luciferase Control Reporter Vector (Promega; cat. #E2261) and pLV-beta-catenin ΔN90 (RRID:Addgene_36985) using Lipofectamine 2,000 reagent (Thermo Fisher Scientific; cat. #11668019). .. The pcDNA/Myc DeltaN TCF4 expression vector (RRID:Addgene_16513) was transfected to express dominant-negative TCF4. .. Luciferase activity was measured with DualLuciferase reagent (Promega; product code E1910) according to the manufacturer’s instructions.

    Transfection:

    Article Title: Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in <i>APC</i>-Mutated Colorectal Cancer
    Article Snippet: HEK 293T cells were seeded in 24-well plates and transfected with luciferase reporter vectors of pGL3-Basic (Promega; cat. #E1751), pGL3-hTDO2 promoter, or pGL3-hTDO2 promoter with a mutated TCF4 binding site with pRL Renilla Luciferase Control Reporter Vector (Promega; cat. #E2261) and pLV-beta-catenin ΔN90 (RRID:Addgene_36985) using Lipofectamine 2,000 reagent (Thermo Fisher Scientific; cat. #11668019). .. The pcDNA/Myc DeltaN TCF4 expression vector (RRID:Addgene_16513) was transfected to express dominant-negative TCF4. .. Luciferase activity was measured with DualLuciferase reagent (Promega; product code E1910) according to the manufacturer’s instructions.

    Dominant Negative Mutation:

    Article Title: Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in <i>APC</i>-Mutated Colorectal Cancer
    Article Snippet: HEK 293T cells were seeded in 24-well plates and transfected with luciferase reporter vectors of pGL3-Basic (Promega; cat. #E1751), pGL3-hTDO2 promoter, or pGL3-hTDO2 promoter with a mutated TCF4 binding site with pRL Renilla Luciferase Control Reporter Vector (Promega; cat. #E2261) and pLV-beta-catenin ΔN90 (RRID:Addgene_36985) using Lipofectamine 2,000 reagent (Thermo Fisher Scientific; cat. #11668019). .. The pcDNA/Myc DeltaN TCF4 expression vector (RRID:Addgene_16513) was transfected to express dominant-negative TCF4. .. Luciferase activity was measured with DualLuciferase reagent (Promega; product code E1910) according to the manufacturer’s instructions.



    Similar Products

    pcdna myc deltan tcf4 expression vector  (Addgene inc)
    93
    Addgene inc pcdna myc deltan tcf4 expression vector
    Figure 2. <t>TCF4/TCF7L2</t> mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.
    Pcdna Myc Deltan Tcf4 Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcdna+myc+deltan+tcf4+expression+vector/pcDNA%2FMyc+DeltaN+TCF4+(Plasmid+%2316513)/10__1158_slash_2159___8290__cd___21___0680-318-1-6
    Average 93 stars, based on 1 article reviews
    pcdna myc deltan tcf4 expression vector - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2. TCF4/TCF7L2 mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.

    Journal: Cancer Discovery

    Article Title: Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer

    doi: 10.1158/2159-8290.cd-21-0680

    Figure Lengend Snippet: Figure 2. TCF4/TCF7L2 mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.

    Article Snippet: The pcDNA/Myc DeltaN TCF4 expression vector (RRID:Addgene_16513) was transfected to express dominant-negative TCF4.

    Techniques: Western Blot, Quantitative RT-PCR, Expressing, Sequencing, Binding Assay, ChIP-sequencing, Negative Control, Luciferase, Activity Assay, Dominant Negative Mutation